Searched for
ENVAFOLIMAB
Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...- Glenmark initiates multi-nation Phase 3 clinical trial for lung cancer drugGlenmark Pharmaceuticals has commenced a Phase 3 clinical trial across multiple countries, including India, Russia, Brazil, and Mexico, for...
- Glenmark Pharma shares in focus as Q1 profit slumps 86% YoYGlenmark Pharma reported an 86% YoY drop in Q1FY26 net profit to Rs 46.9 crore, even as revenue stayed flat at Rs 3,264 crore. EBITDA slipp...
- US prospects, new drugs make Glenmark look betterGlenmark's marketing portfolio as of December 2024 had 201 generic products authorised for distribution in the US. The company has 51 appli...
- Reduce Glenmark Pharmaceuticals, target price Rs 1,265: ICICI SecuritiesICICI Securities maintains a Reduce call on Glenmark Pharmaceuticals with a target price of Rs 1,265. The current market price is Rs 1365.9...
- Glenmark to focus on becoming branded company, says Glenn SaldanhaGlenmark Pharmaceuticals, having navigated recent challenges, is shifting its focus to branded products for higher profit margins. The comp...
- Glenmark Q1 Results: Net profit doubles to Rs 340 croreGlenmark Pharma net profit doubled to Rs 340 crore crore in Q1FY25 led by robust sales growth in India and Europe and reduction in finance,...
- Glenmark Pharma Q4 Results: Net loss widens to Rs 121 crore YoYGlenmark Pharma Q4 Results: The rise in loss was on account of declining sales in the US and exceptional items. It had reported a net loss ...
- Glenmark inks licensing pact with Jiangsu Alphamab, 3D Medicines for cancer drugGlenmark Pharmaceuticals Ltd announced that its subsidiary, Glenmark Specialty S A (GSSA), has entered into a license agreement with Jiangs...
Load More
